Vinton Zachary, Wolfe Kevin, Fisher Jensen, Brooks Amanda
College of Osteopathic Medicine, Rocky Vista University, Parker, CO 80112, USA.
Department of Library Services, Rocky Vista University, Parker, CO 80112, USA.
J Clin Med. 2023 Apr 5;12(7):2717. doi: 10.3390/jcm12072717.
Calcific aortic valve disease (CAVD) is a debilitating condition for which there are limited therapeutic options aside from valve replacement. As such, it is crucial to explore alternative management strategies for CAVD. Non-steroidal anti-inflammatory drugs (NSAIDs), particularly celecoxib, have been the subject of debate in the literature regarding their potential impact on CAVD. We conducted an in-depth analysis of five studies exploring the effect of celecoxib on CAVD and found discrepancies in both methods and results. Our findings suggest that celecoxib may impact the development of this disease via multiple mechanisms, each of which may have different effects on its pathogenesis. We also discovered limited clinical research examining the connection between celecoxib use and CAVD in medical patients. As such, further studies are needed to clarify the role of celecoxib and other NSAIDs in CAVD progression in order to inform future treatment options and clarify their impact on the disease.
钙化性主动脉瓣疾病（CAVD）是一种使人衰弱的病症，除了瓣膜置换外，针对该病的治疗选择有限。因此，探索CAVD的替代管理策略至关重要。非甾体抗炎药（NSAIDs），尤其是塞来昔布，在文献中一直是关于其对CAVD潜在影响的争论焦点。我们对五项探索塞来昔布对CAVD影响的研究进行了深入分析，发现方法和结果均存在差异。我们的研究结果表明，塞来昔布可能通过多种机制影响这种疾病的发展，每种机制对其发病机制可能有不同影响。我们还发现，关于塞来昔布使用与内科患者CAVD之间联系的临床研究有限。因此，需要进一步研究以阐明塞来昔布和其他NSAIDs在CAVD进展中的作用，为未来的治疗选择提供依据，并阐明它们对该疾病的影响。
